EMPA-REG OUTCOME: empagliflozin in type 2 diabetes with heart disease

6.4% of US adults with type 2 diabetes would qualify — about 1.8 million people. Rules that cut the most: Has heart disease or had a stroke; Blood sugar (HbA1c) in the trial's range: 7–9%, or 7–10% if on treatment; BMI 45 or below.

Turn on JavaScript to see the full sample report and download the PDF.